Investors
2026 Cardio Diagnostics, Inc.


For clinical stakeholders, our tests deliver evidence-based insights derived from patients' epigenetic and genetic biomarkers. For non-clinical stakeholders, our population and biopharma platforms transform complex molecular data into meaningful, data-driven intelligence.

Article
Using conventional methods, patients with low risk for CHD sometimes present with acute events, while others thought to be at high risk may remain eve…